trending Market Intelligence /marketintelligence/en/news-insights/trending/oZFDRRHbEhUjpwXBqNNZIg2 content esgSubNav
In This List

Acceleron drops muscular disorder drug after disappointing phase 2 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acceleron drops muscular disorder drug after disappointing phase 2 trial

Cambridge, Mass.-based Acceleron Pharma Inc. said it will discontinue development of its drug for a muscular disorder as it did not achieve statistically significant improvements in the phase 2 trial.

The investigational drug, named ACE-083, was evaluated against placebo for the treatment of facioscapulohumeral muscular dystrophy, or FSHD.

FSHD is a disorder characterized by muscle weakness and wasting which commonly affects muscles around the face, shoulder blades and in the upper arms.

The trial met its main goal as ACE-083 showed a significant increase in mean total muscle volume; however, the increase failed to translate into significant improvements in functional tests. As a result, the clinical-stage biopharmaceutical company will not conduct further trials of the drug for treating FSHD.

Meanwhile, Acceleron is expecting results of a phase 2 trial of ACE-083 in patients with Charcot-Marie-Tooth disease — a neuromuscular disorder characterized by progressive loss of muscle tissue as well as loss of sensation across various parts of the body — in the first quarter of 2020.

Acceleron Pharma's stock price fell by 6.83% to $41.6 as of 6:55 p.m. ET on Sept. 16.